$CHRS Cashflow Statement | Understand Stock

$CHRS

$1.07 +$0.06 (5.94%) Close

$CHRS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net income
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Write-off of prepaid manufacturing services related to the termination of CHS-2020
Write-down of intangible assets and remeasurement of contingent consideration liabilities, net
Write-down of intangible assets and contingent consideration, net
Loss on debt extinguishment
Gain on Sale Transactions, net (Note 6)
Inventory write-downs, net
Non-cash amortization of premium (accretion of discount) on marketable securities, net
Non-cash interest expense from amortization of debt and other financial liabilities discount and issuance costs
2029 Term Loans
Total non-cash interest expense from amortization of debt and other financial liabilities discount and issuance costs
Non-cash operating lease expense
Option payment to Junshi Biosciences
Change in fair value of derivatives
Other non-cash adjustments, net

Changes in operating assets and liabilities:
Trade receivables, net
Inventory
Prepaid manufacturing
Other prepaid, current and non-current assets
Accounts payable
Accrued rebates, fees and reserves
TSA related operating assets and liabilities, net
Accrued compensation
Accrued and other current and non-current liabilities
Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from disposal of property and equipment
Purchases of investments in marketable securities
Proceeds from maturities of investments in marketable securities
Proceeds from sale of investments in marketable securities
Cash received from Sale (Note 6)
CIMERLI ophthalmology franchise
YUSIMRY Sale
Cash and cash equivalents acquired as part of the Surface Acquisition
Upfront and option payments to Junshi Biosciences
Milestone based license fee payments
Net cash received related to the Sale Transactions (Note 6)
Milestone payments to Junshi Biosciences
Other investing activities, net
Net cash provided by investing activities

Financing activities
Proceeds from 2029 Term Loans, net of debt discount and issuance costs
2027 Term Loans
2029 Term Loans
Total proceeds from 2029 Term Loans, net of debt discount and issuance costs

Proceeds from Revenue Purchase and Sale Agreement, net of issuance costs
Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs
Proceeds from issuance of common stock under Private Placement, net of issuance costs
Proceeds from issuance of common stock under ATM Offering, net of issuance costs
Proceeds from issuance of common stock upon exercise of stock options
Proceeds from purchase under the employee stock purchase plan
Taxes paid related to net share settlement
Principal payments for finance lease obligations
Other financing activities, net
Net cash used in financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Right-of-use assets obtained in exchange for lease obligations related to operating leases
Right-of-use assets obtained in exchange for lease obligations related to finance leases
Income taxes paid (refunded), net

Supplemental disclosures of non-cash activities
Purchase of property and equipment in accounts payable and accrued liabilities
Capitalized and accrued milestone payment during the period to Junshi Biosciences
Stock issued under Optional Stock Purchase Agreement
Non-cash employee bonuses settled in common stock

Comments